secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-007858
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports FY2021 net loss of $57.8M; cash at $314.1M; PC14586 data expected H1 2022
--------------------------------------------------------------------------------

- Net loss $57.8M in FY2021 vs $34.4M in FY2020; R&D expenses $36.5M; G&A $21.8M.
- Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2021 vs $361.4M Dec 31, 2020; net cash used in operations $46.6M.
- Lead candidate PC14586 Phase 1/2 trial ongoing; initial Phase 1 data expected in first half of 2022.
- Advanced WIP1 inhibitor program into lead optimization; appointed Kirsten Flowers to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/0001564590-22-007858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/pmvp-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-007858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer